Iovance Biotherapeutics, Inc. IOVA Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s deferred tax assets?
- Iovance Biotherapeutics, Inc. (IOVA) reported deferred tax assets of $30.61M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s deferred tax assets changed year-over-year?
- Iovance Biotherapeutics, Inc.'s deferred tax assets decreased by 4.2% year-over-year, from $31.96M to $30.61M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s deferred tax assets?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s deferred tax assets has grown at a 52.6% compound annual growth rate (CAGR), from $55.93M to $130.15M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.